Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics

Bristol Myers shares fall after a failed trial. This is our plan for the stock

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics

Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA approved Cobenfy as a standalone schizophrenia treatment. The post Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics appeared first on MedCity News.

Has trial result burst BMS' Cobenfy bubble?

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

Bristol Myers’ prized schizophrenia drug stumbles in testing

A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.

Bristol’s Cobenfy disappoints as supplemental antipsychotic drug

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday.

Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test

Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study. The post Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test appeared first on Investor's Business Daily.